This study investigates the effects of using a lower dose of stereotactic radiosurgery, such as Gamma Knife or Linear Accelerator, for patients with brain metastases who are also receiving immunotherapy. Brain metastases occur when cancer cells spread from their original site to the brain. The study aims to understand if a lower dose can be effective and safe.
Participants will have a blood sample taken and information collected from their medical records. They will receive stereotactic radiosurgery tailored to the size of their brain tumors. Follow-up includes regular clinical exams and brain MRIs with contrast, starting one month after treatment and continuing every three months for one year.
- Who can participate: Adults aged 18 years and older with 1 to 10 solid tumor brain metastases can participate. Those with existing autoimmune diseases are not eligible.
- Study details: Participants will undergo standard care procedures, including blood sampling and medical record review. They will receive a lower dose of stereotactic radiosurgery, which is not standard care.
- Study Timelines: The study will last one year.
How understandable was the trial content above?
Hard to understand
Easy to understand
